Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Inhibikase Therapeutics's total assets was $163.59M at Jun 30, 2026. For fiscal 2025 it was $181.20M, up 83.8% from the year before. The highest annual figure on record is $181.20M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $181.20M | +83.8% |
| FY2024 | Dec 31, 2024 | $98.60M | +579.7% |
| FY2023 | Dec 31, 2023 | $14.51M | -41.8% |
| FY2022 | Dec 31, 2022 | $24.94M | -41.3% |
| FY2021 | Dec 31, 2021 | $42.47M | +187.3% |
| FY2020 | Dec 31, 2020 | $14.78M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $163.59M | +84.1% |
| Q1 FY2026 | Mar 31, 2026 | $173.33M | +83.8% |
| Q4 FY2025 | Dec 31, 2025 | $181.20M | +83.8% |
| Q3 FY2025 | Sep 30, 2025 | $79.59M | +1718.5% |
| Q2 FY2025 | Jun 30, 2025 | $88.85M | +906.6% |
| Q1 FY2025 | Mar 31, 2025 | $94.28M | +751.8% |
| Q4 FY2024 | Dec 31, 2024 | $98.60M | +579.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.38M | -75.5% |
| Q2 FY2024 | Jun 30, 2024 | $8.83M | -60.5% |
| Q1 FY2024 | Mar 31, 2024 | $11.07M | -60.7% |
| Q4 FY2023 | Dec 31, 2023 | $14.51M | -41.8% |
| Q3 FY2023 | Sep 30, 2023 | $17.88M | -37.4% |
| Q2 FY2023 | Jun 30, 2023 | $22.35M | -34.3% |
| Q1 FY2023 | Mar 31, 2023 | $28.16M | -26.6% |
| Q4 FY2022 | Dec 31, 2022 | $24.94M | -41.3% |
| Q3 FY2022 | Sep 30, 2022 | $28.58M | -41.9% |
| Q2 FY2022 | Jun 30, 2022 | $33.99M | +186.3% |
| Q1 FY2022 | Mar 31, 2022 | $38.39M | +159.7% |
| Q4 FY2021 | Dec 31, 2021 | $42.47M | – |
| Q2 FY2021 | Jun 30, 2021 | $49.22M | – |
| Q1 FY2021 | Mar 31, 2021 | $11.87M | – |
| Q4 FY2020 | Dec 31, 2020 | $14.78M | – |
See a number that looks wrong?